Skip to content
Menu
September 18, 2025
OWP Pharmaceuticals Announces FDA Approval of SUBVENITE® (lamotrigine) Oral Suspension
Share this press release:
Document loads below this notification.
If you are not able to see the document below, please reload page.
×
Prev
Previous PR
Next PR
Next
Additional Press Releases
January 12, 2026
/
Press Release
OWP Pharmaceuticals Announces Commercial Product Availability of SUBVENITE® (lamotrigine) Oral Suspension in U.S. Market
May 20, 2024
/
Press Release
OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension
August 1, 2023
/
Press Release
OWP Pharmaceuticals Announces IND Authorization for First Oral Liquid Formulation of Trazodone for Treatment of MDD
View All Press Releases
View All Press Releases
CloseMenu
About Us
Our Purpose
Our People
Leadership Team
Board of Directors
FAQs
Products
Subvenite Oral Suspension
Subvenite Starter Kits
Lamotrigine Starter Kits
Roweepra IR
Our Future
Pipeline
News
Press Releases
Events
Connect
Careers
Contact Us
© 2025 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
© 2025 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
© 2025 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
